Table 1.
Expert physician author experience with Fabry disease and migalastat (n = 3 co-chairs; n = 11 expert panelists).
| Country | |
| Argentina | 1 |
| Brazil | 1 |
| Canada | 1* |
| France | 1 |
| Italy | 1 |
| Norway | 1 |
| Portugal | 1 |
| Spain | 1 |
| Taiwan | 2 |
| United Kingdom | 1* |
| United States | 3* |
| Specialty† | |
| Cardiology | 1 |
| Genetics | 5* |
| Hematology | 1* |
| Lysosomal diseases | 1 |
| Metabolism | 2 |
| Nephrology | 4* |
| Neurology | 1 |
| Pediatrics | 3* |
| Internal medicine | 2 |
| Duration of Fabry disease clinical experience, years | |
| Mean (SD) | 20 (6) |
| 0–10 | 0 |
| 11–20 | 7 |
| 21–30 | 7 |
| >30 | 0 |
| Experience with migalastat (research, managing patients), years | |
| Mean (SD) | 7 (4) |
| 0–5 | 8 |
| 5–10 | 3 |
| >10 | 3 |
| Number of patients with Fabry disease managed | |
| Mean (SD) | 123 (121) |
| 1–10 | 0 |
| 11–50 | 4 |
| 51–100 | 4 |
| >100 | 6 |
| Summary of patients managed, mean (range) | |
| Male | 55 (12–200) |
| Female | 64 (0–300) |
| Classic | 69 (10–250) |
| Non-classic | 50 (2–250) |
*Indicates n = 1 co-chair; †Some experts have multiple specialties.
SD, standard deviation.